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Abstract 
Background: Antimicrobial resistance is fueled by inappropriate use of antibiotics. Global and national strategies 
support rational use of antibiotics to retain treatment options and reduce resistance. In Germany, the ARena project 
(Sustainable reduction of antibiotic‑induced antimicrobial resistance) intended to promote rational use of antibiotics 
for acute non‑complicated infections by addressing network‑affiliated physicians, primary care teams and patients 
through multiple interacting interventions. The present study documented patterns of antibiotic prescribing for 
patients with acute non‑complicated infections who consulted a physician in these networks at the start of the ARena 
project. It explored variation across subgroups of patients and draws comparisons to prescribing patterns of non‑
targeted physicians.
Methods: This retrospective cross‑sectional analysis used mixed logistic regression models to explore factors associ‑
ated with the primary outcome, which was the percentage of patient cases with acute non‑complicated respiratory 
tract infections consulting primary care practices who were treated with antibiotics. Secondary outcomes concerned 
the prescribing of different types of antibiotics. Descriptive methods were used to summarize the data referring to 
targeted physicians in primary care networks, non‑targeted physicians (reference group), and patient subgroups.
Results: Overall, antibiotic prescribing rates were 32.0% in primary care networks and 31.7% in the reference group. 
General practitioners prescribed antibiotics more frequently than other medical specialist groups (otolaryngologists 
vs. General practitioners OR = 0.465 CI = [0.302; 0.719], p < 0.001, pediatricians vs. General practitioners: OR = 0.369 
CI = [0.135; 1.011], p = 0.053). Quinolone prescribing rates were 9.9% in primary care networks and 8.1% in reference 
group. Patients with comorbidities had a higher likelihood of receiving an antibiotic and quinolone prescription and 
were less likely to receive a guideline‑recommended substance. Younger patients were less likely to receive antibi‑
otics (OR = 0.771 CI = [0.636; 0.933], p = 0.008). Female gender was more likely to receive an antibiotic prescription 
(OR = 1.293 CI = [1.201, 1.392], p < 0.001).
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Background
The use of antibiotics in German primary care is lower 
than average in other countries [1, 2] but there is still 
potential for lowering prescribing rates for specific con-
ditions. In light of growing antimicrobial resistance, the 
holistic German national antibiotic resistance strategy 
(DART 2020) follows the One Health approach to pro-
mote awareness, counteract microbial resistance and 
preserve antibiotic treatment options [3]. Monitoring 
the use of antibiotics is an important strategy to reduce 
the spread of antimicrobial resistance, particularly in 
primary care where about 85% of the used antibiotics in 
Germany are prescribed [4, 5]. Antibiotics are prescribed 
in 41% of GP consultations for acute respiratory tract 
infections (ARTI) [4]. Only 52% of these prescriptions are 
in accordance with prevailing clinical recommendations 
[6].
In recent years, several research projects tested strat-
egies that aim to enhance the rational and appropri-
ate use of antibiotics in healthcare. In this context, the 
three-armed, cluster randomized trial ARena (Sustain-
able reduction of antibiotic-induced antimicrobial resist-
ance; conducted from 2017 to 2020) aimed to foster the 
rational use of antibiotics for acute non-complicated 
respiratory tract infections in primary care in Germany 
[7]. By applying a multifaceted strategy with multiple 
interacting intervention components, ARena addressed 
primary care physicians, care teams as well as patients 
[7]. An innovative aspect of ARena was its embedding 
in 14 primary care networks (PCNs) across two German 
federal states. PCNs can be described as formalized col-
laborations of economically independent physicians and 
other healthcare providers working in single or joint 
practices who interact regularly, share patients, standard-
ize treatment and care according to evidence-based prac-
tice guidance, regularly attend continuing education, and 
discuss concerns if these arise. They give support regard-
ing practice management and quality improvement [8] 
and therefore were expected to amplify the impact of the 
ARena implementation program. More detailed descrip-
tion of the study design and interventions can be found 
elsewhere [7].
Previous research investigated the development of 
antibiotic prescribing rates in primary care and found 
a relatively stable utilization in Germany from 2008 to 
2014 [9]. However, strong variations of overall and age-
group-specific distributions of antibiotic subgroups 
could be identified [10]. A strong awareness of antimi-
crobial resistance has been observed among German 
General Practitioners (GPs), while measures to improve 
rational prescribing were found to be not widely imple-
mented [11]. In more recent research, a 5-year cohort 
study of antibiotic prescribing rates by family physi-
cians in Ontario, Canada, aimed to describe predictors 
of antibiotic prescribing and inter-physician variability 
in antibiotic prescribing. It was concluded that observed 
substantial inter-physician variability in antibiotic pre-
scribing could not be explained by sociodemographic 
and clinical patient characteristics [12]. Further recent 
research also found that the use of antibiotics in German 
primary care showed large variations between and within 
medical specialties and seasons, and that a considerable 
proportion of antibiotic prescribing lacked conformity 
with national guideline recommendations [13]. Though 
these study findings might not reflect the most current 
situation or guideline-conformity of prescribing, there 
is an indication that antibiotics are still not prescribed 
appropriately regarding indication and spectrum and 
thus are frequently used inappropriately. For targeted 
quality improvement, it is relevant to know which sub-
groups of patients and physicians are at highest risk of 
inappropriate utilization of antibiotics.
For the ARena study, the outcome evaluation is based 
on quarterly claims-data as provided by a large German 
statutory health insurer and references established indi-
cators of the European Surveillance of Antimicrobial 
Consumption Network (ESAC-Net) [14] which were tai-
lored to the specifics of the study. Primary and secondary 
outcomes are related to general prescribing of systemic 
antibiotics as well as indication-specific prescribing of 
antibiotics currently recommended [15, 16] by German 
clinical guidelines [15, 16]. To explore the actual anti-
biotic prescribing rates in the participating PCNs and 
their determinants, this present study aimed to define 
the baseline antibiotic prescribing rates as percentage of 
cases with acute non-complicated respiratory tract infec-
tions prior to the start of the ARena project and explore 
potential percentage variation across the intervention 
Conclusion: This study provided an overview of observed antibiotic prescribing for acute non‑complicated respira‑
tory tract infections in German primary care at the start of the ARena project. Findings indicate potential for improve‑
ment and will serve as comparator for the post‑interventional outcome evaluation to facilitate describing of potential 
changes.
Keywords: Antimicrobial resistance, Antibiotic prescribing, Acute upper respiratory tract infections, Primary care, 
Mixed logistic regression model
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arms, medical specialties and subgroups of patients. 
Also, this baseline situation was to be compared to a non-
PCN standard care reference group (RG), using the pro-
vided claims data and considering characteristics such as 
patient age, gender and insurance and health status.
Methods
Study design
This retrospective cross-sectoral analysis was based on 
claims data regarding antibiotic prescribing in primary 
care at the start of a prospective interventional trial (Q3 
2016–Q2 2017). The outcomes evaluation (Trial reg-
istration: ISRCTN, ISRCTN58150046) is designed as 
a three-armed cluster randomized trial with fourteen 
PCNs and RG that reflects standard care in two German 
federal states (Bavaria and North Rhine-Westphalia). 
The ARena-study was approved by the ethics commit-
tee of the Medical Faculty of the University of Heidelberg 
(reference number: S-353/2017). The study was planned 
with an intervention period (Q4 2017–Q2 2019), and two 
parts of evaluation: (a) an outcome evaluation based on 
quarterly claims-data (two measuring points: baseline Q3 
2016–Q2 2017; post-interventional Q3 2018–Q2 2019), 
and (b) a process evaluation based on surveys [7].
Study population
All PCNs situated in Bavaria and North Rhine-West-
phalia with a valid contract with AOK referring to a spe-
cific healthcare delivery program (defined by German law 
§ 140a SGB V a.F. and § 140a Abs. 1. S. 2 Alt. 1 SGB V 
n.F) were contacted by mail by the aQua Institute, Göt-
tingen, Germany, for study participation. Fourteen PCNs 
were recruited to participate in the ARena study and 
randomized to the intervention arms (arm I = 4 PCNs; 
arm II = 5 PCNs; arm III = 5 PCNs). For administrative 
reasons, the focus was on their patients insured by the 
statutory health insurer AOK and registered within the 
specific healthcare delivery program. Around 35% of the 
population within geographic reach of the participating 
PCNs in Bavaria alone are insured by AOK [7]. At base-
line, approximately 40,000 patients with AOK health 
insurance were registered in 196 participating primary 
care practices in these 14 networks. Medical special-
ties of the participating physicians included (n = 309) 
were general practice, otolaryngology, pediatrics, urol-
ogy and gynecology. The patient population for the three 
intervention arms comprised patient cases who sought 
primary care for one of the following reasons: acute non-
complicated upper respiratory tract infections (URTI), 
bronchitis, sinusitis, tonsillitis and otitis media. Thus, 
patient study populations differed per indexed consulta-
tion reason regarding number of cases, age of patients 
and insurance status. The diagnoses were based on 
physician-recorded ICD-10 codes and the prescribing 
information in administrative data provided by the statu-
tory health insurer AOK for quarterly reimbursement 
periods which were linked by the pseudonymized patient 
individual insurance number. Each physician-recorded 
ICD-10 code for the defined index diagnoses represents 
a case, where each patient can produce multiple cases. 
A patients’ case is recorded for each ICD-10 code within 
each quarter. Prescribing information was derived from 
quarterly claims data as provided by the health insurer 
and included patient cases were not actively recruited. 
Consent for data inclusion in the analysis was obtained, 
an additional written informed patient consent was pre-
requisite in North Rhine-Westphalia.
Measures
The primary outcome in this study was the baseline pre-
scribing rate as percentage of cases of all patients with 
acute respiratory tract infections consulting primary 
care practices who were treated with systemic antibiot-
ics without pathogen detection. More precise, patients 
suffering from acute bronchitis (18–75  years), sinusitis 
(> 18  years), otitis media (> 2  years), acute URTI (acute 
rhino-pharyngitis, pharyngitis) (> 1  year), or tonsilli-
tis (> 1  year) were considered in the primary outcome. 
Due to the structure of the provided quarterly claims 
data and data protection regulations, ICD-10 codes and 
antibiotic prescriptions were matched for each quarter 
of year, which means that each patient can provide one 
case per quarter because the direct connection of ICD-
10 code and antibiotic prescription is not possible. Phy-
sician-recorded diagnoses that warrant antibiotic therapy 
were not included for analysis. Specifically excluded were 
diagnoses for streptococcal tonsilitis and other patho-
gen-caused acute forms of tonsillitis. (Additional file  1: 
Table  S1 details included diagnoses and related ICD-10 
codes, Table S2 provides a list of excluded diagnoses.)
The following secondary outcomes regarding acute 
non-complicated infections were examined:
1. Percentage of cases who received guideline-recom-
mended antibiotics for acute
– URTI (> 1 year; recommendation: amoxicillin)
– Bronchitis (18–75  years; recommendation: amoxi-
cillin, tetracycline, macrolides)
– Sinusitis (> 18 years; recommendation: amoxicillin, 
cefuroxime)
– Tonsillitis (> 1  year; recommendation: penicillin, 
erythromycin)
– Otitis- Otitis media (> 2  years; recommendation: 
amoxicillin, erythromycin, cefuroxime)
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2. Percentage of cases who received a prescription for 
quinolones
3. Consumption of broad-spectrum antibiotics in 
Defined daily dose (DDD%) on practice level (beta-
lactam-beta-lactamase inhibitor combinations, 
cephalosporines of 2nd, 3rd and 4th generation, mac-
rolides (excluding Erythromycin) and gyrase inhibi-
tors (fluoroquinolones)
Further secondary outcomes considered by the study 
protocol referred to cystitis and community-aquired 
pneumonia and were not explored due to very small 
numbers of recorded cases. Patient age specifications for 
all observed sub-groups follow the study protocol [7]. 
Categorization of recommended antibiotics was based on 
existing evidence-based clinical guidelines developed by 
the German College of General Practitioners and Family 
Physicians (DEGAM) [16] and the Association of the Sci-
entific Medical Societies in Germany (AWMF) [15]. (See 
Additional file  1: Table  S3 for currently recommended 
and alternative antibiotics.)
Regarding patients, the following sociodemographic, 
disease, and treatment characteristics in the claims 
data provided by AOK were included: age, sex, Charl-
son comorbidity index (CCI) (predicts 1-year survival 
in patients based on sum of relevant comorbidities [17, 
18], employment status, nationality (missing values 
aggregated to ‘other’), insurance status (main member, 
family, retiree), participation in a disease management 
program (DMP) which is a structured treatment plan to 
support management of chronic disease and maintain 
and improve quality of life [19] (type 1 diabetes, type 2 
diabetes, coronary heart disease, breast cancer, bronchial 
asthma, COPD, cardiac insufficiency), classified degree 
of necessary nursing care [20], and season. Regarding 
primary care practices, type of location (urban, increas-
ingly urbanized, countryside), type of practice (single or 
group) and medical specialty group are documented.
Data analysis
The baseline data were analyzed regarding the four quar-
ters prior to the ARena intervention (Q3 2016–Q2 2017) 
with a focus on prescribing rates of antibiotics for acute 
non-complicated self-limiting infections in the interven-
tion arms and the RG that reflects standard care. In addi-
tion, patients’ sociodemographic and disease-specific 
characteristics in either of these groups are summarized. 
Also focused are the use of guideline-recommended 
indication-appropriate antibiotics and the group of 
quinolones.
The primary and all secondary outcomes, as well 
as all documented data (patient characteristics, dis-
ease characteristics, treatment data, and practice 
characteristics), were first analyzed descriptively. For 
continuous variables, mean and standard deviation, 
median, 25%/75%-quantiles [Q1–Q3], min and max are 
provided, for categorical variables absolute and relative 
frequencies are given. Note that the description of patient 
and disease characteristics, as well as treatment data and 
practice characteristics differ between outcomes, because 
the considered cases are defined for each outcome by 
respective index diagnoses and antibiotic prescribing. 
Therefore, the descriptive analysis is done for each out-
come individually. For the subgroups gender, DMP and 
the CCI, the primary and all secondary outcomes are 
contrasted using descriptive methods based on patients 
in PCNs and RG.
A logistic mixed effects regression model was used 
to investigate factors which may influence the primary 
outcome. The model considers the nested structure of 
the data with patients nested in practices, which means 
practice is included as random effect in the logistic mixed 
effects model. As fixed effects, medical specialty group 
(German: Fachgruppe—FGR), urbanization, age group, 
sex, and the CCI as indication of health status are consid-
ered, the selection is based on clinical expertise. Second-
ary outcomes are analyzed using mixed logistic (1.–2.) 
or beta regression models (3.). Adjustment is done as 
described for the primary outcome model. Since this is 




The primary analysis considered a total of 3,129,289 
cases in PCNs (n = 18,207) and the RG (n = 3,111,082) 
diagnosed with one of the indexed infections (tonsillitis, 
sinusitis, otitis media, bronchitis, and URTI). In PCNs, 
92.7% of the participating practices were General Prac-
titioners, 4.9% Otolaryngologists, and 2.1% were Pedia-
tricians. In the RG, 73.3% were General Practitioners, 
10.6% Otolaryngologists and 14.5% were Pediatricians. 
The total number of observed cases mentioned above 
(n = 3,129,289) reflects 2 102 783 patients with a mean 
of 1.5 cases per patient. In PCNs, 62.8% of the included 
cases were seen in rural area practices compared to 32.6% 
of cases in the RG. Mean age of patients was higher in 
PCNs. In both groups, sex was equally distributed. 
Patient nationality was not reported for less than 1% of 
the cases and all cases without this information are con-
sidered in the category “other”. Cases in PCNs were older 
and with a higher morbidity, except for Otitis media 
where cases were included from the age of two and above. 
A main group difference in terms of insurance status was 
apparent in the subgroup of retired insurance members 
(RG: 10.3%; PCNs 20.8%). Distribution of cases with 
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indexed diagnoses and sociodemographic characteristics 
of patients in PCNs and RG are presented in Table 1.
Primary outcome
The observed baseline antibiotic prescribing rate as per-
centage of all cases with acute non-complicated respira-
tory tract infections was slightly higher in PCNs (32.0%) 
than in RG (31.7%). Across all observed infections and 
cases, GPs were the largest group of treating physicians 
to prescribe antibiotics. In PCNs, the percentage ranged 
from 87.3 to 99.7%, in the RG the range was lower and 
between 46.9 and 96.7% (See Additional file 1: Table S5 
for details on the overall distribution of medical spe-
cialty of antibiotics prescribing physicians.). In mixed 
logistic regression models for the primary outcome in 
PCNs, the specialist group otolaryngologists (OR = 0.465 
CI = [0.302; 0.719], p-value < 0.001) and pediatri-
cians (OR = 0.369 CI = [0.135; 1.011], p-value = 0.007) 
appeared to prescribe antibiotics less frequently com-
pared to GPs (see Table 2). Looking at patients, women 
were more likely to receive antibiotics compared to men 
(OR = 1.293 CI: [1.201; 1.392], p-value < 0.001). Patients 
under 18  years were less likely than patients aged 18 
to 65 to receive an antibiotic prescription (OR = 0.771 
CI: [0.636; 0.933], p-value = 0.008). An increased CCI 
implied higher prescribing rates. Table  2 shows results 
of the mixed logistic regression model for antibiotic pre-
scribing rates in the PCNs for acute upper respiratory 
tract infections using practice and patient-related charac-
teristics as covariates.
For the DMPs for Type 2 Diabetes mellitus, asthma, 
COPD and coronary heart disease, the inclusion of cases 
across all PCNs was > 90%. In the RG, highest inclusion 
was for the DMP Asthma (76.8% of the observed cases). 
In PCNs, 46% of observed cases were registered in a Type 
1 Diabetes mellitus DMP, in RG only 17.7% of the cases 
were in a DMP. In PCNs, 10.9% of cases were in a breast 
cancer DMP, in RG this percentage was 5.1%.
The different levels of needed nursing care (level 1 to 5) 
were equally distributed across groups. Additionally, the 
CCI of patients in PCNs showed higher relative frequen-
cies in high index values and lower relative frequencies in 
Table 1 Sociodemographic characteristics of all cases in RG and 
PCNs (n = 3,129,289) and distribution per indexed diagnoses
Cases RG PCNs
Age: Mean (SD) 34.3 (21.07) 47.5 (18.94)
Sex: Female n (%) 1,633,772 (52.5) 10,594 (58.2)
Nationality: n (%)
 German 2,353,362 (75.6) 15,980 (87.8)
 Eastern European 548,307 (17.6) 1630 (9.0)
 Southern European 109,871 (3.5) 355 (1.9)
 Northern European 29,508 (0.9) 79 (0.4%)
 Other 70,034 (2.3) 163 (0.9)
Insurance status: n (%)
 Main member 1,857,770 (59.7) 12,278 (67.4)
 Family member 876,894 (28.2) 2024 (11.1)
 Retired member 319,600 (10.3) 3787 (20.8)
Employment “yes”: n (%) 1,881,657 (60.5) 12,143 (66.7)
Upper respiratory tract infections % 69.2 65.3
Bronchitis % 24.1 29.3
Sinusitis % 7.7 10.1
Tonsilitis % 8.6 5.6
Otitis media % 7.0 4.7
Table 2 Results of the logistic mixed effects regression model for prescribing of antibiotics in PCNs for acute non‑complicated 
respiratory tract infections
vs versus, PCN primary care network
Odds ratio Lower CI limit Upper CI limit Standard error p-value
Otolaryngologists vs general practitioner 0.465 0.302 0.719 0.222  < 0.001
Pediatrician vs general practitioner 0.369 0.135 1.011 0.514 0.053
Other specialty groups vs general practitioner 0.251 0.075 0.844 0.618 0.026
Increasingly urbanized vs rural location 0.832 0.512 1.351 0.248 0.457
Urban vs rural location 0.901 0.693 1.192 0.138 0.489
PCN size medium vs small 0.960 0.634 1.453 0.212 0.846
PCN size large vs small 1.009 0.671 1.517 0.208 0.967
Patient age < 18 vs 18–65 0.771 0.636 0.933 0.098 0.008
Patient age > 65 vs 18–65 1.077 0.967 1.200 0.055 0.179
Female patients vs male patients 1.293 1.201 1.392 0.038  < 0.001
Charlson Index 1 and 2 vs 0 1.562 1.436 1.700 0.043  < 0.001
Charlson Index 3 and 4 vs 0 1.662 1.435 1.925 0.075  < 0.001
Charlson Index >  = 5 vs 0 1.760 1.505 2.059 0.080  < 0.001
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low index values compared to RG. This indicates a higher 
burden of morbidity in the patient sample in PCNs. The 
percentage of included cases who needed extended care 
in a nursing home was 0.6% in PCNs (n = 116) and 0.4% 
in RG (n = 13,513). Table 3 details health status across all 
cases regarding cases included in Disease Management 
Programs (DMP), nursing care level, and Charlson co-
morbidity index. (See Additional file 2 for detailed infor-
mation on CCI per observed infection and respective 
patient population.)
Secondary outcomes
Regression analysis for prescribing of guideline-recom-
mended antibiotics did not identify common influenc-
ing factors over all considered infections (see Additional 
file  2). Pediatricians seemed to prescribe more recom-
mended antibiotics compared to general practitioners 
for patients suffering from URTI. For bronchitis, older 
patients (> 65  years) had a lower probability to receive 
a recommended antibiotic prescription compared to 
patients with age 18–65. Detailed results regarding pre-
scribing of guideline-recommended antibiotics (1st 
choice and alternatives) across all observed cases in 
PCNs and RG are given in Table 4. Listed values repre-
sent prescribing of one total year.
Overall, quinolones were prescribed in 9.9% of cases 
in PCNs and 8.1% in RG and thus, generally moderate to 
low. In PCNs, prescribing of quinolones was observed in 
11.3% of cases with bronchitis and 9.5% of the cases with 
URTI (in RG 11.4% and 7.7%). Viewed separately, 4.9% of 
Otitis Media cases, 3.6% of Tonsillitis cases, and 11.2% 
of Sinusitis cases received a prescription for quinolo-
nes in PCNs. With 5.3%, 2.7%, and 9.5%, the respective 
proportions of quinolone prescribing were somewhat dif-
ferent in RG. In mixed logistic regression models for qui-
nolone prescribing for patients treated with antibiotics in 
PCNs, patients in increasingly urbanized areas seemed to 
be less likely to receive a prescription for quinolones. An 
increased CCI implied higher probability for prescrib-
ing quinolones compared to a CCI of 0 (no comorbidity). 
Detailed results of the logistics mixed effects model are 
given in Table 5. (See Additional file 1: Table S4 for diag-
noses that warrant quinolone prescribing.)
On practice level, the prescribing of broad-spectrum 
antibiotics in DDD% were higher in PCNs (Median 
[Q1–Q3]: 100% [82.4–100]) compared to RG (Median 
[Q1–Q3]: 95.9% [66.1–100]). Beta regression models on 
practice level indicated that specialist groups had a lower 
prescribing rate of broad-spectrum antibiotics than GPs. 
(See Additional file 2: Table S17).
Table 3 Distribution of disease management programs and health status across all cases
*The nursing care level reflects the extent to which patients are able to manage their own needs independently. Based on an expected care dependency of at least 
6 months, evaluation takes six main aspects into account: mobility, cognitive and communicative abilities, behavioral and psychological issues, self‑care, management 
of disease‑related demands and burden, and arrangements of daily life and social contacts [21]
Health status RG PCN
Disease Management
Program (DMP): n (%)
Diabetes Type 2: 2,140,035 (68.8) Diabetes Type 2: 16,754 (92.0)
Asthma: 2,388,555 (76.8) Asthma: 16,913 (92.9)

















Charlson Index: n (%) 0: 2,178,429 (70.0)
1, 2: 757,952 (24.4)
3, 4: 105,140 (3.4)
 > 5: 69,561 (2.2)
0: 10,059 (55.2)
1, 2: 5482 (30.1)
3, 4: 1334 (7.3)
 > 5: 1332 (7.3)
Table 4 Prescribing of guideline‑recommended antibiotics 
across all cases
RG  reference group representing standard care, PCN  primary care network
*Diagnoses for streptococcal tonsilitis and other pathogen‑caused acute forms 
of tonsillitis that warrant antibiotic therapy are not included
**No alternative choices defined
RG cases 1st choice/ 
alternative choice/ 
total
PCN cases 1st choice/ 
alternative choice/ 
total
Tonsillitis %* 24.0/ 3.8 / 27.8 18.8/ 1.2 / 20
Sinusitis % 18.7/ 40.6 / 59.3 22.1/ 42.2 / 64.3
Otitis media % 41.0/ 32.4 / 73.4 28.6/ 37.5 / 66.1
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The descriptive subgroup analyses over all patients 
(PCNs and RG) support the findings of the regression 
models. Detailed results of the descriptive subgroups 
analysis corresponding to the primary and secondary 
outcomes are shown in Additional file  2. The rates of 
guideline-recommended substances were comparable 
between genders. Contrasting the participation in DMPs 
resulted in a small increase in the rate of antibiotics and 
quinolones for DMP participants, and smaller rates of 
recommended (alternative) antibiotics for indexed diag-
noses. A clear difference is observed for CCI 0 (without 
comorbidity) versus higher values. Antibiotics and qui-
nolone prescribing rates were more than 10% higher for 
patients with comorbidities and less recommended sub-
stances were used for those patients.
Discussion
This study explored baseline antibiotic prescribing rates 
in PCNs at the start of the ARena project regarding cases 
with acute non-complicated respiratory tract infections. 
In about a third of all observed cases, patients received 
an antibiotic. Younger patients were less likely to receive 
antibiotics. More antibiotics were prescribed to female 
than to male patients. GPs were the largest included 
group of prescribers and prescribed antibiotics more fre-
quently than other medical specialists. Prescribing rates 
for quinolones were moderate, and patients with comor-
bidities had a higher likelihood of receiving an antibiotic 
and quinolone prescription and less likely to receive a 
guideline-recommended substance.
Rates of antibiotic prescribing in German primary care 
overall have been decreasing constantly between 2010 
and 2018, particularly with regards to children and ado-
lescents [22] who were underrepresented in this study 
sample. Room for improvement can be expected to be 
more visible in ‘high prescribers’, but since the potential 
for improvement noticeably decreased in recent years 
already, nevertheless, there remains substantial room for 
further reduction of antibiotic prescribing.
A recent national cross-sectional study in USA identi-
fied that 57% of 130.5 million prescriptions for antibiot-
ics written during ambulatory care visits in 2015 were for 
appropriate indications, 25% were inappropriate and 18% 
had no documented indication. It was noted that being 
an adult male, spending more time with the provider and 
seeing a non-primary care specialist were significantly 
positively associated with non-indicated antibiotic [23]. 
In contrast to these findings, our data indicate that anti-
biotics were most frequently prescribed by general prac-
titioners. In addition, the prescribing of broad-spectrum 
antibiotics showed slightly higher rates in PCNs com-
pared to RG. These discrepancies in antibiotic prescrib-
ing rates between PCNs and RG might be explained by 
the differing specialist group distribution between PCNs 
and RG and a small percentage of specialists and a higher 
percentage of GPs in PCNs than RG. A contributing fac-
tor towards the slight difference in prescribing rates 
between PCNs and RG can also be seen in higher patient 
age and morbidity in PCNs which is in line with findings 
of Shaver et  al. [24] who recently examined antibiotic 
prescribing in the outpatient setting in USA. Exception 
here in our study is prescribing for Otitis media where 
cases were included from the age of two and above and 
therefore morbidity considerations cannot deliver expla-
nations for higher prescribing rates in PCNs. Prescribing 
rates for quinolones were generally moderate to low in 
PCNs (9.9%) and RG (8.1%) and thus also match findings 
of the study from USA where in 9.4% of investigated visits 
for acute respiratory infections a broad-spectrum antibi-
otic was received [24]. Prescribing quinolones seemed to 
Table 5 Results of the logistic mixed effects regression model for prescribing rates of quinolones for patients treated with antibiotics 
in PCNs
vs  versus, PCN  primary care network
Covariate OR Lower CI limit Upper CI limit Standard error p-value
Other spec. groups vs.* General Practitioner 0.617 0.277 1.374 0.408 0.237
Urbanization vs.* rural location 0.466 0.210 1.035 0.407 0.061
Urban vs. rural 0.558 0.371 0.840 0.209 0.005
PCN size medium vs*. small 1.975 1.028 3.793 0.333 0.041
PCN size large vs.* small 1.077 0.565 2.053 0.329 0.821
Patient age > 65 vs.*
age <  = 65
1.294 0.997 1.679 0.133 0.053
Female patients vs.* Male patients 0.928 0.757 1.136 0.104 0.467
Patients with Charlson Index 1 and 2 vs.*0 1.864 1.469 2.366 0.122  < 0.001
Patients with Charlson Index 3 and 4 vs.* 0 3.114 2.196 4.418 0.178  < 0.001
Patients with Charlson Index >  = 5 vs.* 0 3.264 2.245 4.746 0.191  < 0.001
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be associated with a higher number of comorbidities and 
higher patient age as well which complements findings 
of the process evaluation conducted alongside ARena 
where uncertainty about diagnoses, prognosis, conti-
nuity of care and perceptions about patient preferences 
were found to be among the reasons for non-indicated 
prescribing [25, 26]. To some extend this confirms find-
ings from a 2010 study that investigated fluoroquinolone 
prescribing for acute cough in German primary care to 
find predictors for unjustified prescribing. The research-
ers then concluded that unjustified quinolone prescrib-
ing was determined by patient characteristics such as 
severity and duration of illness and patient age. However, 
they also found that physicians with higher individual 
antibiotic prescribing rates and physicians with hospi-
tal-based specialty training—versus combined hospital 
and ambulatory training—were more likely to prescribe 
fluoroquinolones than physicians who specifically trained 
as GPs [27]. Interestingly, our data showed that in PCN 
practices in locations with increasing urbanization, qui-
nolone prescribing rates were lower than in rural loca-
tions. This complements results from a previous study 
where German GPs working in urban areas were found 
to be more likely to use the strategy of delayed prescrib-
ing of antibiotics than GPs working in rural areas [11]. 
Such discrepancies between urban and rural prescribing 
habits potentially could root in more ample opportunities 
for self-reflection about prescribing motivated by regu-
lar peer exchange and a broader and more frequent offer 
of continued training and upskilling in urban locations. 
Efforts to educate physicians, care teams and patients 
continuously about current and appropriate diagnosis 
and therapy options as well as communication about 
them may remedy this to some extent.
The perceived, but not actually communicated patient 
request for antibiotics is often overrated by physicians 
[28] and may initiate unfounded assumptions of los-
ing patients to another physician when therapy followed 
guideline recommendations and antibiotics are not pre-
scribed. In this study, the rate for prescribing of guide-
line-recommended antibiotics was remarkably low and 
in line with the high rate for broad-spectrum antibiotics 
on practice level which is another potential indicator for 
physicians’ uncertainty. Though quinolone prescribing 
was moderate overall, patients with higher comorbidity 
and patients participating in DMPs were more likely to 
receive a quinolone prescription, and less likely to receive 
one of the guideline-recommended substances. This 
might be related to higher age and poorer health status 
of these patients as supported by previous research [24], 
but also to the physicians’ striving for the elimination of 
both their own and patients’ insecurities and potential 
complications. One effective way to eliminate insecurities 
and reduce prescribing of antibiotics was found to be the 
promotion of communication skills by means of a short 
communication training for primary care physicians [29, 
30]. In a recent study in Germany, results showed a pre-
scribing probability decrease of 6.5 percentage points for 
the treatment of URTI and an even stronger impact for 
female patients aged below 35 [31]. As the ARena project 
also used an intervention component to strengthen com-
munication skills, similar effects can be expected.
The rate of prescribed broad-spectrum antibiotics in 
PCNs in this study seemed slightly higher compared to 
the study by Shaver et al. conducted in USA [24]. How-
ever, for this present study the outcome was assessed by 
DDD% on practice level whereas Shaver et al. evaluated 
on patient level. Factors associated with the prescribing 
of guideline-recommended antibiotics for the considered 
infections could not be clearly identified. Information 
about patient nationality was not available for all cases, 
yet the percentage of nationalities other than German 
was low. However, our data showed that the percent-
age of observed cases of Eastern European patients was 
higher than the one of Southern Europeans in PCNs as 
well as in RG. This is contrasted by findings of the pro-
cess evaluation in ARena where physicians indicated 
their subjective perception of many Southern Europeans 
asking for antibiotics [25].
Strengths and limitations
One strength of this study is the careful exclusion of 
cases where there was an ICD-10 code documented that 
indicates antibiotic prescribing. Additionally, the type of 
antibiotics (recommended, quinolones, broad- versus 
small-spectrum) were analyzed in detail. A limitation of 
this retrospective cross-sectoral analysis of baseline data is 
the restriction on ICD-10 codes and claims-related health 
insurance data. Therefore disease, patient, and practice 
information are limited. Direct connection between ICD-
10 code and prescription of antibiotics is not possible in 
the provided claims data, thus ICD-10 codes and antibi-
otics prescription were matched by quarter which intro-
duces a potential bias. To compensate, diagnoses that 
warranted antibiotic therapy were excluded. The use of 
DDDs for pediatric antibiotic consumption where weight-
based dosing is appropriate, is an additional limitation. 
Participating practices and PCNs were already recruited 
for the ARena trial and might be more alert to the topic 
and supportive of appropriate prescribing already (shared 
attitude in the networks that might only be attractive for 
certain physicians). So far only one time point before the 
planned intervention in the ARena trial could be ana-
lyzed. Final assessment of effects will be possible through 
the analysis of post intervention data with a focus on 
the evaluation of the interventions. The baseline data 
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included patients and practices as clustering levels. Since 
only a small number of patients produced more than one 
case, patients were not considered as random intercept 
in the model. P-values are of secondary interest since the 
population considered here is very large and p-values get 
very small even for small differences. Findings of this pre-
sent study can then serve as comparator in the final report 
of the outcome evaluation.
Conclusion
Primary care antibiotic prescribing rates for acute non-
complicated respiratory tract infections were moder-
ate prior to the intervention start of the ARena project, 
but indicate room for improvement. Lower rates for 
guideline-recommended substances indicate a need for 
creating stronger awareness of guideline-conform use of 
antibiotics as intended by the implementation program 
used in ARena. This baseline assessment of prescribing 
will serve as comparator in the post-interventional out-
come evaluation and support describing of potentially 
observed effects of the program.
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